α－干扰素治疗慢性粒细胞白血病内生LAK细胞活性与细胞遗传学变化的关系  

RELATION BETWEEN ENDOGENOUS LYMPHOKINE ACTIVATED KILLER CELL ACTIVITY AND CYTOGENETIC RESPONSE IN CBRONIC MYELOGENOUS LEUKAEMIA TREATED WITH INTERFEREN

作　　者：徐娟[1] 崔晓华[1] 李亚林[1] 田丁[1] 薛惠华[1] 

机构地区：[1]北京首都医科大学宣武医院血液科,北京军事医学科学院放射医学研究所

出　　处：《中国免疫学杂志》1996年第6期381-383,共3页Chinese Journal of Immunology

摘　　要：观察了１０例。α－干扰素治疗慢性粒细胞白血病时，内生ＬＡＫ细胞活性与细胞遗传学缓解的关系。其结果为干扰素治疗前慢性粒细胞白血病（ＣＭＬ）患者无内生ＬＡＫ细胞活性。于干扰素治疗后逐渐出现内生ＬＡＫ细胞活性，在６例检测出ＬＡＫ细胞活性的病例中均出现不同程度的ｐｈ阳性细胞比例下降，从而推测，α－干扰素治疗ＣＭＬ时部分病人细胞遗传学缓解可能与α－干扰素诱生体内ＬＡＫ细胞增多参与肿瘤免疫应答反应有关。Had observed that endogenous lymphokine activated killer(LAK)cell activity and cytogenetic response in 10 patients of chronic myelogenous leukaemia (CML)treated with α-Interferon(α-IFN).The results are no any LAK cell activity in l0 patients before the treatment with IFN,and could detected LAK activity in 6 patients after treatment with IFN. The latter were tested using NK-resistant(Raji)cell line in a target-cell colony growth inhibition assay. 6 patients underwent partial cytogenetic remission together with significantly high LAK activity.These observation could favor the hypothesis of an indirect effect of α-INF on ph'positive leukemic cells mediated by cell involved in tumor immune surveillance.

关 键 词：白血病 药物疗法 Α-干扰素 LAK细胞 细胞遗传学 

分 类 号：R733.705[医药卫生—肿瘤]